Educational content, not medical advice. This article reports marketing status as the FDA's labeling database showed it on November 2, 2026, and reports companies' stated reasons as they were reported. A discontinued medicine is a prescriber conversation, and nothing here suggests a substitute.

Old names resurface constantly: a forum thread from a few years back, an article that never went offline, a line on an old prescription record. Tanzeum. Bydureon. Adlyxin. Whether a name still corresponds to a marketed medicine is a factual question with a checkable answer, and checking it is a skill that outlasts any single product. Every status below was verified against the FDA's labeling database, DailyMed, on November 2, 2026, which is the honest way to state any of it: as a snapshot of a database on a date, not as a permanent fact about a market.

What the database showed

Four searches, four different situations:

  • Albiglutide, sold as Tanzeum. A DailyMed search for albiglutide returns zero results. No current US label exists.
  • Exenatide extended-release, sold as Bydureon and Bydureon BCise. Searches for bydureon, and for exenatide extended-release, return zero results. The once-weekly form of exenatide has no current US label.
  • Exenatide twice daily. Still listed, and listed twice: the AstraZeneca Byetta label and a generic exenatide injection from Amneal. The Byetta listing carries a marketing end date of 31 December 2026, while the Amneal generic lists a marketing start of 22 November 2024 with no end date.
  • Lixisenatide, sold as Adlyxin. One result only, and it is Soliqua, the fixed combination of insulin glargine and lixisenatide. No standalone lixisenatide product has a current US label.

The exenatide entry is the one worth a second look, because it is two stories in one molecule. The weekly form has no label at all, while the twice-daily form carries both a winding-down brand listing and a new generic with an open-ended start date. Departure and arrival, in the same molecule, in the same database.

The reasons, as they were reported

GSK announced the Tanzeum withdrawal in 2017, and it has been consistently reported as a commercial decision rather than a safety one, with supply running out over the following year. AstraZeneca notified the FDA that it discontinued both Bydureon BCise and Byetta in late October 2024, reported as a business decision. These are reported reasons, attributed to the companies and to the coverage of their announcements. What can be said flatly is that none of the departures in this list is a safety story, and none should be read as one. By the same token, the survival of the current products says nothing about their safety either: older medicines leaving is not evidence that newer ones are safer.

The trial that reported a benefit after the withdrawal

Albiglutide's cardiovascular outcomes trial, Harmony Outcomes, was published in The Lancet. It randomised 9,463 patients across 28 countries, followed them for a median of 1.6 years, and concluded that albiglutide was superior to placebo with respect to major adverse cardiovascular events. The trial was funded by GlaxoSmithKline, the same company that had already announced it was withdrawing the drug.

Sit with the sequence. A company decides a medicine is not worth selling, and the outcomes trial for that same medicine then reports a cardiovascular benefit, in a top journal, funded by the departing company itself. Nothing about that pairing is contradictory, because the two events answer different questions. A withdrawal answers whether a medicine can be sold profitably in a competitive market; an outcomes trial answers whether it worked in the population studied. A medicine's disappearance is a commercial fact, not a verdict on whether it worked, and albiglutide is the cleanest illustration of that difference anywhere in the class. What cardiovascular outcome trials measure, and how to read their headlines, is covered at GLP-1s and the Heart: What the Outcome Trials Showed.

GLP 1 Tracker AppDated dose entries with notes for the medicines you take now, so when a regimen changes, the record shows what changed and when. Free, no account, nothing leaves your phone. Get the app

How to check any medicine's current status

The transferable part is short. Current US labels live in the FDA's labeling database, DailyMed, and a search by drug name is the check. A product with no current label is not being marketed in the United States. And a listing can carry a marketing end date while the page is still visible, which is exactly what the Byetta listing shows: the page exists, and the page itself says the marketing ends on 31 December 2026. The listing is the thing to read, not the mere fact that a page loads. The same caution runs the other way. A search for retatrutide, a medicine with no FDA approval at all, now returns listings filed under the marketing category export only, which covers products registered for shipment outside the United States and is not an approval of any kind. That one is unpacked at Retatrutide: What to Know About the Triple Agonist. The same database is where the current version of any label lives, which is one of the habits taught in How to Read Your GLP-1's Prescribing Information.

Why medicines leave, and what it means if you took one

In general, medicines leave markets for commercial decisions, competition, manufacturing problems, or a safety signal, and the cases here sit in the first two. None involves a withdrawal for safety reasons. The counter-current matters as much as the departures: while the weekly form of exenatide left, the twice-daily form gained a generic from Amneal, and generic liraglutide arrived in the same period, a story told at Generic Liraglutide: The First Generic GLP-1. Arrivals and departures were happening in the same market at the same time, which is what a market in transition looks like from the label database.

For a person who was taking one of these medicines, the next step is the same regardless of which one it was: a conversation with the prescriber who manages that regimen now. A discontinued medicine raises real questions about what comes next, and those questions are answered with a full medical history, not with an article or a forum thread. Nothing here suggests a substitute for any of them. What the short-acting agents are, and how the surviving one differs from the weekly medicines most people now take, is covered at Byetta and the Short-Acting GLP-1s.

Frequently asked questions

Was Tanzeum withdrawn for safety reasons?

No safety withdrawal has been reported. GSK announced the Tanzeum withdrawal in 2017, and it has been consistently reported as a commercial decision rather than a safety one, with supply running out over the following year. As reported reasons go, that one is explicit. A DailyMed search for albiglutide now returns zero results, meaning no current US label exists, and none of the departures covered here has been reported as a safety story.

Can you still get Byetta in the United States?

As of November 2, 2026, Byetta still has a current label: the AstraZeneca listing carries a marketing end date of 31 December 2026. Alongside it, a generic exenatide injection from Amneal lists a marketing start of 22 November 2024 with no end date. What that means for a specific prescription is a question for a prescriber or pharmacist, who can see supply in a way no article can.

Is Adlyxin still available?

A DailyMed search for lixisenatide returns one result, and it is Soliqua, the fixed combination of insulin glargine and lixisenatide. No standalone lixisenatide product has a current US label, so the Adlyxin name does not correspond to a currently marketed standalone product. A record showing Adlyxin is a prescriber conversation rather than a pharmacy errand.

How can I check whether a GLP-1 is still on the market?

Search the FDA's labeling database, DailyMed, by drug name. A product with no current label is not being marketed in the United States. One caution from the Byetta listing: a page can remain visible while carrying a marketing end date, so the listing itself is the thing to read, not its mere existence. What the database shows is a snapshot, and the honest way to cite it is with the date you checked.

Why would a GLP-1 that worked leave the market?

Because commercial decisions, competition and manufacturing shape what is sold, independent of whether a medicine worked. Albiglutide is the sharp example: its cardiovascular outcomes trial, Harmony Outcomes, randomised 9,463 patients across 28 countries and concluded albiglutide was superior to placebo for major adverse cardiovascular events, and it was published after GSK had already announced the withdrawal. Disappearance is a commercial fact, not a verdict on efficacy.